001 | 120596 | ||
005 | 20240228145455.0 | ||
024 | 7 | _ | |a 10.1007/s00259-016-3594-z |2 doi |
024 | 7 | _ | |a pmid:27988802 |2 pmid |
024 | 7 | _ | |a 0340-6997 |2 ISSN |
024 | 7 | _ | |a 1432-105X |2 ISSN |
024 | 7 | _ | |a 1619-7070 |2 ISSN |
024 | 7 | _ | |a 1619-7089 |2 ISSN |
024 | 7 | _ | |a altmetric:17885527 |2 altmetric |
037 | _ | _ | |a DKFZ-2017-01024 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Freitag, Martin |0 P:(DE-He78)c420f6efccb409e1a287be027501a74c |b 0 |e First author |
245 | _ | _ | |a Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. |
260 | _ | _ | |a Heidelberg [u.a.] |c 2017 |b Springer-Verl. |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1660815008_8349 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a The positron emission tomography (PET) tracer (68)Ga-PSMA-11, targeting the prostate-specific membrane antigen (PSMA), is rapidly excreted into the urinary tract. This leads to significant radioactivity in the bladder, which may limit the PET-detection of local recurrence (LR) of prostate cancer (PC) after radical prostatectomy (RP), developing in close proximity to the bladder. Here, we analyze if there is additional value of multi-parametric magnetic resonance imaging (mpMRI) compared to the (68)Ga-PSMA-11-PET-component of PET/CT or PET/MRI to detect LR.One hundred and nineteen patients with biochemical recurrence after prior RP underwent both hybrid (68)Ga-PSMA-11-PET/CTlow-dose (1 h p.i.) and -PET/MRI (2-3 h p.i.) including a mpMRI protocol of the prostatic bed. The comparison of both methods was restricted to the abdomen with focus on LR (McNemar). Bladder-LR distance and recurrence size were measured in axial T2w-TSE. A logistic regression was performed to determine the influence of these variables on detectability in (68)Ga-PSMA-11-PET. Standardized-uptake-value (SUVmean) quantification of LR was performed.There were 93/119 patients that had at least one pathologic finding. In addition, 18/119 Patients (15.1%) were diagnosed with a LR in mpMRI of PET/MRI but only nine were PET-positive in PET/CT and PET/MRI. This mismatch was statistically significant (p = 0.004). Detection of LR using the PET-component was significantly influenced by proximity to the bladder (p = 0.028). The PET-pattern of LR-uptake was classified into three types (1): separated from bladder; (2): fuses with bladder, and (3): obliterated by bladder). The size of LRs did not affect PET-detectability (p = 0.84), mean size was 1.7 ± 0.69 cm long axis, 1.2 ± 0.46 cm short-axis. SUVmean in nine men was 8.7 ± 3.7 (PET/CT) and 7.0 ± 4.2 (PET/MRI) but could not be quantified in the remaining nine cases (obliterated by bladder).The present study demonstrates additional value of hybrid (68)Ga-PSMA-11-PET/MRI by gaining complementary diagnostic information compared to (the 68)Ga-PSMA-11-PET/CTlow-dose for patients with LR of PC. |
536 | _ | _ | |a 315 - Imaging and radiooncology (POF3-315) |0 G:(DE-HGF)POF3-315 |c POF3-315 |f POF III |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
650 | _ | 7 | |a (68Ga)Glu-urea-Lys(Ahx)-HBED-CC |2 NLM Chemicals |
650 | _ | 7 | |a Organometallic Compounds |2 NLM Chemicals |
700 | 1 | _ | |a Radtke, Jan Philipp |0 P:(DE-He78)79897f8897ff77676549d9895258a0f2 |b 1 |
700 | 1 | _ | |a Afshar-Oromieh, Ali |0 P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c |b 2 |
700 | 1 | _ | |a Roethke, Matthias C |0 P:(DE-HGF)0 |b 3 |
700 | 1 | _ | |a Hadaschik, Boris A |b 4 |
700 | 1 | _ | |a Gleave, Martin |b 5 |
700 | 1 | _ | |a Bonekamp, David |0 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93 |b 6 |
700 | 1 | _ | |a Kopka, Klaus |0 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |b 7 |
700 | 1 | _ | |a Eder, Matthias |0 P:(DE-He78)331382460d902d1341dc73db8b990f97 |b 8 |
700 | 1 | _ | |a Heusser, Thorsten |0 P:(DE-He78)a00a109668c5fdbeea213d6981588250 |b 9 |u dkfz |
700 | 1 | _ | |a Kachelriess, Marc |0 P:(DE-He78)f288a8f92f092ddb41d52b1aeb915323 |b 10 |
700 | 1 | _ | |a Wieczorek, Kathrin |b 11 |
700 | 1 | _ | |a Sachpekidis, Christos |0 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2 |b 12 |
700 | 1 | _ | |a Flechsig, Paul |b 13 |
700 | 1 | _ | |a Giesel, Frederik |0 P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94 |b 14 |
700 | 1 | _ | |a Hohenfellner, Markus |b 15 |
700 | 1 | _ | |a Haberkorn, Uwe |0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |b 16 |
700 | 1 | _ | |a Schlemmer, Heinz-Peter |0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |b 17 |
700 | 1 | _ | |a Dimitrakopoulou-Strauss, A. |0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992 |b 18 |e Last author |
773 | _ | _ | |a 10.1007/s00259-016-3594-z |g Vol. 44, no. 5, p. 776 - 787 |0 PERI:(DE-600)2098375-X |n 5 |p 776 - 787 |t European journal of nuclear medicine and molecular imaging |v 44 |y 2017 |x 1619-7089 |
909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:120596 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)c420f6efccb409e1a287be027501a74c |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)79897f8897ff77676549d9895258a0f2 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)331382460d902d1341dc73db8b990f97 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)a00a109668c5fdbeea213d6981588250 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)f288a8f92f092ddb41d52b1aeb915323 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Imaging and radiooncology |x 0 |
914 | 1 | _ | |y 2017 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2015 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2015 |
920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l E010 Radiologie |x 0 |
920 | 1 | _ | |0 I:(DE-He78)E060-20160331 |k E060 |l E060 KKE Nuklearmedizin |x 1 |
920 | 1 | _ | |0 I:(DE-He78)E030-20160331 |k E030 |l Radiopharmazeutische Chemie |x 2 |
920 | 1 | _ | |0 I:(DE-He78)E020-20160331 |k E020 |l E020 Med. Physik in der Radiologie |x 3 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)E010-20160331 |
980 | _ | _ | |a I:(DE-He78)E060-20160331 |
980 | _ | _ | |a I:(DE-He78)E030-20160331 |
980 | _ | _ | |a I:(DE-He78)E020-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|